HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Humacyte, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.40−0.03 (-6.50%)

Close on Oct 19, 2026

Market cap: $93.93M
P/E (TTM): –
Dividend yield: –

Humacyte, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	9.75	6.14	6.83	6.18	10	4.69
Change in Accounts Receivable	-0.26	0	0.03	0.15	-0.06	0.49
Change in Inventory	-22	0	–	–	–	–
Change in Accounts Payable	0.97	-1.96	4.81	-0.51	-0.20	-0.89
Operating Cash Flow	-105	-98	-73	-71	-81	-56
Capital Expenditures	-0.88	-1.57	-2.28	-1.05	-0.22	-0.32
Sale of Property, Plant & Equipment	–	–	–	–	0	0.05
Purchase of Investments	–	–	0	-10	-8.00	0
Investing Cash Flow	-0.88	-1.57	-0.17	4.85	-8.22	-0.27
Stock Issued	–	–	–	–	242	0
Debt Issued	–	–	–	–	0	3.25
Debt Repaid	-88	0	–	–	–	–
Financing Cash Flow	61	114	4.51	-1.45	267	2.05
Net Change in Cash	-44	14	-69	-68	178	-54
Free Cash Flow	-106	-100	-76	-72	-81	-56
Income Taxes Paid	0	0	–	–	–	–
Interest Paid	–	0	1.61	2.67	1.12	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -494.6%
Operating margin: -5240.8%
Net margin: -4560.8%
Return on equity, FY2025: 164.8%

Financial strength

Current ratio: 6.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 534.5%

Valuation

P/E ratio: –
Price to sales: 44.29
Price to book: 3.00
Dividend yield: –